跳到主要内容
知仓学习社ZHICANG

kidney-international

Use when targeting Kidney International or deciding whether a nephrology or hypertension clinical/translational study fits this venue. Encodes the j…

不碰外部(只输出文字)无严重或高危命中brycewang-stanford/Awesome-Journal-Skills

它会碰到什么

扫了多少1 个文本文件,8 KB
它会碰到什么不碰外部(只输出文字)
命中总数0 处
命中统计严重 0 · 高 0 · 中 0 · 低 0

这一栏是扫描器报的事实,不是结论。命中多不等于有毒(安全工具、规则库、示例脚本本来就会包含危险写法),命中少也不等于干净。它和你手上的凭据、文件、网络有什么关系,需要你自己看。

技能内容

Kidney International (kidney-international)

Journal positioning

Kidney International is the flagship journal of the International Society of Nephrology

(ISN), publishing high-impact nephrology and hypertension research with an explicitly

global, international perspective across clinical and translational science: kidney

disease epidemiology and trials, dialysis and transplantation, and mechanistic kidney

biology with clear human relevance. Its defining expectation is a **clinically or

translationally important advance in kidney health that matters across diverse health

systems and populations**, with strong representation of global-health, epidemiologic,

and outcomes nephrology alongside disease mechanism — not a narrow single-center series

or a basic experiment with no human anchor. Compared with the U.S.-society sibling, KI

leans toward international clinical breadth and translational relevance. This skill is a

fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and

does not replace the journal's current instructions for authors. Before submitting,

re-check the live Kidney International author instructions.

When to trigger

  • The author names Kidney International for a nephrology, hypertension, or kidney

translational study and wants a fit/framing check.

  • A kidney study must be re-framed around international clinical relevance, outcomes, or

disease mechanism with human anchoring.

  • The author is choosing between Kidney International and the Journal of the American

Society of Nephrology (ASN flagship), or general medicine.

  • The author needs the journal's reporting-guideline, registration, and global-health/

epidemiology expectations.

Scope & topic fit

  • Clinical nephrology and hypertension: CKD, AKI, glomerular disease, and blood-pressure/

kidney interactions across diverse populations.

  • Kidney-disease epidemiology and global-health nephrology: burden, access, and outcomes

across health systems and resource settings.

  • Dialysis and transplantation: outcomes, modality, access, and organ-preservation

research with international relevance.

  • Translational kidney science: biomarkers, genetics/genomics, and mechanism studies with

validated human relevance.

  • Clinical trials and large multinational cohorts with kidney endpoints.
  • Hypertension and cardio-renal research connecting kidney function to systemic outcomes.

Method & evidence bar

  • Clinical studies must be adequately powered with prespecified, patient-centered kidney

endpoints; trials require prospective registration and the registration number.

  • The applicable reporting guideline and checklist are expected: CONSORT for trials,

STROBE for observational/epidemiologic work, PRISMA for systematic reviews, ARRIVE for

animal studies.

  • Epidemiologic and global-health studies must address representativeness, confounding,

bias, and generalizability across settings explicitly.

  • Translational claims need validated human relevance (tissue, biofluids, or cohorts);

basic experiments need controls and biological replication.

  • Effect estimates need confidence intervals and absolute as well as relative measures;

causal language must match the design.

  • eGFR/biomarker methods, kidney-outcome definitions, and statistical-analysis plans must

be explicit.

Structure & house style

  • ISN format with a structured abstract and a translational/lay-significance statement;

re-check current article types (Clinical Investigation, Basic Research, etc.) and limits

on the live guide.

  • The introduction frames the global clinical or biological gap; the discussion states the

practice implication and bounds generalizability.

  • A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design;

animal work reports ARRIVE-aligned detail.

  • Figures show representative data with statistics and N; a supplement carries full methods,

the protocol/SAP, and additional analyses.

Official-submission checklist

  • Before giving submission-ready advice, read ../../resources/source-basis.md and

../../resources/official-source-map.md; start from the ICMJE/EQUATOR and ISN anchors,

then cite the current Kidney International page you checked.

  • Search the live site for "Kidney International ISN instructions for authors" and follow

the current version.

  • Re-check article types, abstract and significance-statement format, and word/figure/reference limits.
  • Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE),

data/code-availability, and protocol/SAP submission.

  • Re-check IRB/ethics and consent, transplant-donor consent where relevant, animal-care/IACUC

approval, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.

  • If the live official instructions conflict with this skill, the official instructions

win.

Pre-submission self-check

  • [ ] The study delivers a clinically/translationally important kidney finding with relevance across settings.
  • [ ] Clinical kidney endpoints are prespecified and powered; trials are registered with the number in the manuscript.
  • [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached.
  • [ ] Epidemiologic work addresses representativeness, confounding, and generalizability.
  • [ ] Translational claims are anchored to validated human relevance; basic work shows controls and replication.
  • [ ] IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared.

Common desk-reject triggers

  • Single-center descriptive series with limited generalizability and no broader relevance.
  • Epidemiologic analyses with inadequate confounding control or overstated causal claims.
  • Basic experiments with no human anchor, replication, or ARRIVE-aligned rigor.
  • Missing trial registration, protocol, or the required reporting checklist.
  • Incremental dialysis/transplant or hypertension outcome reports with limited novelty or scope.

Re-routing decision

  • U.S.-society, mechanism-forward nephrology with deep basic science → journal-of-the-american-society-of-nephrology.
  • Diabetic kidney disease centered on endocrine/metabolic mechanism → diabetologia / journal-of-clinical-endocrinology-and-metabolism.
  • Critical-care AKI dominated by ICU organ-support → critical-care-medicine / american-journal-of-respiratory-and-critical-care-medicine.
  • Broad practice-changing nephrology trial → general medicine (jama / NEJM / The Lancet in the natural-science bundle).
  • Pure renal cell biology with no disease/population anchor → a basic-science venue in the natural-science bundle.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Kidney International (ISN)
[Specialty tags] <clinical nephrology / hypertension / epidemiology / transplant + global relevance>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / animal-ARRIVE>
[Method/evidence] <power, generalizability, mechanism/human anchoring, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / consent / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>

想直接用这个技能?

本站把开放许可(MIT / Apache 等)的技能按仓库打包整理到网盘,点一下转存到你自己的网盘,不用一个个从 GitHub 拉。许可未声明的技能只给原始仓库链接,不打包。